Trial · NCT04989972
Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults
NCT04989972, Phase 2, Withdrawn, Wake Network, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults. Trials, record NCT04989972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04989972
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults
- NCT number
- NCT04989972
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Wake Network, Inc.
- Conditions
- Anxiety and Depression
- Interventions
- PSIL428, Oyster mushroom, PSIL428
- First posted
- 2021-08-04
- Last updated
- 2022-06-30
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Beck Anxiety Inventory BAI | Screening to week 16 | Measures 21 items in physical and cognitive anxiety ranges 0-7 mild, to 26-63 severe Questionnaire BDI-11 |
| Primary | Changes in Beck Depression Inventory 02 - BDI-II | screening to week 16 | Measures 21 items in the presence and severity of depressive symptoms 0-9 no depression, 10 -18 mild depression, 19-29 moderate to severe depression |
| Secondary | Change in the European Quality of life 5 dimensions- EQ-5D | screening to week 16 | changes between the intervention PSIL-428 and placebo groups for mobility, self-care, pain \& discomfort, usual activities and anxiety \& depression |
| Secondary | Cognitive flexibility, using the Stroop Color & Word Test (SCWT) | Screening to week 16 | Changes in cognition between the PSIL-428 and placebo groups in the reading of words as compared to identifying \& naming colors. A stopwatch is used and the test-taker reads color words or names ink colors from different pages as quickly as possible. An interference score, cognitive flexibility, creativity and reaction to cognitive pressure are measured |
| Secondary | Changes in resilience using the Brief Resiliency Scale | Screening to 16 weeks | assesses the ability of the individual to bounce back or recover from stress a score of one means low resiliency and a score of 5 means high resiliency |
| Secondary | Measurement of higher level cognitive processes using the Wisconsin Card Sorting Test | screen to 16 weeks | Uses two card packs, having 4 stimulus cards and 64 response cards measures attention, perseverance , abstract thinking and set shifting. |
| Secondary | The incidence of adverse events | Screening to 16 weeks | The number of reported cases of adverse events |
| Secondary | The severity of adverse events | Screening to 16 weeks | Adverse events which range from mild,moderate, severe and lethal |
| Secondary | Incidence of abnormal blood pressure | Screening to 16 weeks | Blood pressure which is consistently above and below120/80 |
| Secondary | Incidence of abnormal heart rate | Screening to 16 weeks | The incidence of atrial fibrillation, supraventricular tachycardia or bradycardia |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04989972
GET https://conductscience.org/api/trials/v1/NCT04989972/registered?page=2